🇺🇸 FDA
Pipeline program

GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720

GS-US-695-7156

Phase 3 small_molecule active

Quick answer

GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720 for HIV-1 Infection is a Phase 3 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Gilead Sciences International Limited
Indication
HIV-1 Infection
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials